The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation

Journal of Hepatology

Volumn 55, Issue 6, 2011, Pages 1201-1206

  Nattermann, Jacob ^a   Timm, Jörg ^b   Nischalke, Hans Dieter ^a   Olbrich, Anne ^b   Michalk, Monika ^a   Tillmann, Hans L ^c   Berg, Thomas ^e   Wedemeyer, Heiner ^d   Tenckhoff, Hannelore ^e   Wiese, Manfred ^f   Kullig, Ulrike ^g   Göbel, Uwe ^h   Capka, Emanuela ⁱ   Schiefke, Ingolf ^j   Güthof, Wolfgang ^k   Grüngreiff, Kurt ^l   König, Ingrid ^m   Roggendorf, Michael ^b   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f Hepatologische Schwerpunktpraxis   (Germany)

^g ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^h Gastroenterologische Schwerpunkt Praxis   (Germany)

ⁱ KLINIKUM CHEMNITZ   (Germany)

^j Klinikum St Georg   (Germany)

^k KLINIKUM ERNST VON BERGMANN   (Germany)

^l Gastroenterologische Schwerpunktpraxis   (Germany)

^m Internistische Praxis ^*  (Germany)

more..

Author keywords

Anti D cohort; CCR5; Clearance; Hepatitis C virus; IL28B; Polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CYSTEINE; IMMUNOGLOBULIN D ANTIBODY; INTERLEUKIN 28B; THREONINE;

ADULT; ALLELE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRAL GENETICS; WILD TYPE;

ALLELES; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE OUTBREAKS; DRUG CONTAMINATION; FEMALE; GENE FREQUENCY; GENOTYPE; GERMANY; HEPATITIS C; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR5; SEQUENCE DELETION;

EID: 81355161417     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.03.011     Document Type: Article

References (54)

1. A. Rauch, S. Gaudieri, C. Thio, and P.Y. Bochud Host genetic determinants of spontaneous hepatitis C clearance Pharmacogenomics 10 2009 1819 1837
2. A. Rauch, J. Rohrbach, and P.Y. Bochud The recent breakthroughs in the understanding of host genomics in hepatitis C Eur J Clin Invest 40 2010 950 959
3. C.L. Thio Host genetic factors and antiviral immune responses to hepatitis C virus Clin Liver Dis 12 2008 713 726 xi
4. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
5. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
6. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
7. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, and T. Mueller Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345 [1345 e1331-1337]
8. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
9. H.L. Tillmann, A.J. Thompson, K. Patel, M. Wiese, H. Tenckhoff, and H.D. Nischalke A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice Gastroenterology 139 2010 1586 1592
10. P. Sheppard, W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, and T.E. Whitmore IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68 [Epub 2002 Dec 2002]
11. S.V. Kotenko, G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen, and N.K. Shah IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 2003 69 77
12. T. Marcello, A. Grakoui, G. Barba-Spaeth, E.S. Machlin, S.V. Kotenko, and M.R. MacDonald Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 2006 1887 1898
13. P. Sheppard, W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, and T.E. Whitmore IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68
14. P.L. Shields, C.M. Morland, M. Salmon, S. Qin, S.G. Hubscher, and D.H. Adams Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver J Immunol 163 1999 6236 6243
15. S. Ayehunie, E.A. Garcia-Zepeda, J.A. Hoxie, R. Horuk, T.S. Kupper, and A.D. Luster Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors Blood 90 1997 1379 1386
16. S. Sozzani, P. Allavena, A. Vecchi, and A. Mantovani Chemokines and dendritic cell traffic J Clin Immunol 20 2000 151 160
17. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
18. D. Bell, J.W. Young, and J. Banchereau Adv Immunol. 72 1999 255 324
19. F. Sallusto, and A. Lanzavecchia Mobilizing dendritic cells for tolerance, priming, and chronic inflammation J Exp Med 189 1999 611 614
20. M. Dean, M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, and R. Allikmets Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study Science 273 1996 1856 1862
21. R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, and R. Horuk Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377
22. M. Carrington, T. Kissner, B. Gerrard, S. Ivanov, S.J. O'Brien, and M. Dean Novel alleles of the chemokine-receptor gene CCR5 Am J Hum Genet 61 1997 1261 1267
23. M. Hisada, R.B. Lal, S. Masciotra, D.L. Rudolph, M.P. Martin, and M. Carrington Chemokine receptor gene polymorphisms and risk of human T lymphotropic virus type I infection in Jamaica J Infect Dis 185 2002 1351 1354
24. J.C. Stephens, D.E. Reich, D.B. Goldstein, H.D. Shin, M.W. Smith, and M. Carrington Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes Am J Hum Genet 62 1998 1507 1515
25. J.N. Torimiro, N.D. Wolfe, A. Thomas, M.P. Martin, E. Mpoudi-Ngole, and U. Tamoufe Frequency of CCR5 variants among rural populations with low HIV-1 prevalence in Cameroon AIDS 21 2007 527 528
26. S.K. Cohn Jr. , and L.T. Weaver The Black Death and AIDS: CCR5-Delta32 in genetics and history QJM 99 2006 497 503
27. J. Novembre, A.P. Galvani, and M. Slatkin The geographic spread of the CCR5 Delta32 HIV-resistance allele PLoS Biol 3 2005 e339
28. P.C. Sabeti, E. Walsh, S.F. Schaffner, P. Varilly, B. Fry, and H.B. Hutcheson PLoS Biol 3 2005 e378
29. C.L. Thio, J. Astemborski, A. Bashirova, T. Mosbruger, S. Greer, and M.D. Witt Genetic protection against hepatitis B virus conferred by CCR5Delta32: evidence that CCR5 contributes to viral persistence J Virol 81 2007 441 445
30. F.L. Muntinghe, S. Gross, S.J. Bakker, G.W. Landman, P. van der Harst, and H.J. Bilo CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus Diabetes Res Clin Pract 86 2009 140 145
31. W.G. Glass, D.H. McDermott, J.K. Lim, S. Lekhong, S.F. Yu, and W.A. Frank CCR5 deficiency increases risk of symptomatic West Nile virus infection J Exp Med 203 2006 35 40
32. M. Fischereder, B. Luckow, B. Hocher, R.P. Wuthrich, U. Rothenpieler, and H. Schneeberger CC chemokine receptor 5 and renal-transplant survival Lancet 357 2001 1758 1761
33. R.P. Woitas, G. Ahlenstiel, A. Iwan, J.K. Rockstroh, H.H. Brackmann, and B. Kupfer Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C Gastroenterology 122 2002 1721 1728
34. G. Ahlenstiel, T. Berg, R.P. Woitas, F. Grunhage, A. Iwan, and L. Hess Effects of the CCR5-Delta 32 mutation on antiviral treatment in chronic hepatitis C J Hepatol 39 2003 245 252
35. C. Goulding, R. McManus, A. Murphy, G. MacDonald, S. Barrett, and J. Crowe The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source Gut 54 2005 1157 1161
36. S. Hellier, A.J. Frodsham, B.J. Hennig, P. Klenerman, S. Knapp, and P. Ramaley Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection Hepatology 38 2003 1468 1476
37. K. Promrat, D.H. McDermott, C.M. Gonzalez, D.E. Kleiner, D.E. Koziol, and M. Lessie Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C Gastroenterology 124 2003 352 360
38. M.T. Dorak, G.O. Folayan, S. Niwas, D.J. van Leeuwen, L.J. Yee, and J. Tang C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection Immunol Res 26 2002 167 175
39. J. Glas, H.P. Torok, C. Simperl, A. Konig, K. Martin, and F. Schmidt The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin Clin Immunol 108 2003 46 50
40. A. Goyal, P.V. Suneetha, G.T. Kumar, D.K. Shukla, N. Arora, and S.K. Sarin CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C World J Gastroenterol 12 2006 4721 4726
41. A. Mangia, R. Santoro, L. D'Agruma, and A. Andriulli HCV chronic infection and CCR5-delta32/delta32 Gastroenterology 124 2003 868 869 [author reply 869-870]
42. S. Mascheretti, H. Hinrichsen, S. Ross, P. Buggisch, J. Hampe, and U.R. Foelsch Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients Clin Exp Immunol 136 2004 328 333
43. M. Ruiz-Ferrer, N. Barroso, G. Antinolo, and J. Aguilar-Reina Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies J Viral Hepat 11 2004 319 323
44. I. Thoelen, J. Verbeeck, E. Wollants, P. Maes, G. Robaeys, and C. Mathei Frequency of the CCR5-Delta32 mutant allele is not increased in Belgian hepatitis C virus-infected patients Viral Immunol 18 2005 232 235
45. H.E. Wasmuth, A. Werth, T. Mueller, T. Berg, C.G. Dietrich, and A. Geier CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia J Mol Med 82 2004 64 69
46. M. Zhang, J.J. Goedert, and T.R. O'Brien High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1 Gastroenterology 124 2003 867 868
47. M. Wiese, F. Berr, M. Lafrenz, H. Porst, and U. Oesen Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study Hepatology 32 2000 91 96
48. M. Wiese, K. Grungreiff, W. Guthoff, M. Lafrenz, U. Oesen, and H. Porst Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study J Hepatol 43 2005 590 598
49. H.D. Nischalke, J. Nattermann, M. Lichterfeld, R.P. Woitas, J.K. Rockstroh, and T. Sauerbruch Rapid determination of the Delta32 deletion in the human CC-chemokine receptor 5 (CCR5) gene without DNA extraction by lightcycler real-time polymerase chain reaction AIDS Res Hum Retroviruses 20 2004 750 754
50. M.J. Dolan, H. Kulkarni, J.F. Camargo, W. He, A. Smith, and J.M. Anaya CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms Nat Immunol 8 2007 1324 1336
51. Y. Zhou, T. Kurihara, R.P. Ryseck, Y. Yang, C. Ryan, and J. Loy Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor J Immunol 160 1998 4018 4025
52. G. Ahlenstiel, R.P. Woitas, A. Iwan, J. Nattermann, G. Feldmann, and J.K. Rockstroh Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia Immunol Invest 38 2009 284 296
53. N. Ank, M.B. Iversen, C. Bartholdy, P. Staeheli, R. Hartmann, and U.B. Jensen An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity J Immunol 180 2008 2474 2485
54. M. Honda, A. Sakai, T. Yamashita, Y. Nakamoto, E. Mizukoshi, and Y. Sakai Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509